Iranian Researchers Find New Treatment Method for Arteriosclerosis
“In this study, due to the ineffectiveness of the existing drug delivery systems, specially pegylated nanoparticles, the development of cellular nanospectrums (nano bows) was used to inhibit the inflammatory aspects of atherosclerosis in human ex vivo and rabbit in vivo models, and clearly the effects of survival and reduction of the size of the atherosclerotic plaque and a decrease in inflammation was observed in aortic bifurcations,” said Jalil Mehrzad Salakjani, a professor of the Department of Microbiology and Immunology of the Faculty of Veterinary Medicine of the University of Tehran.
He added that the produced cellular nano-silhouette has a monocyte membrane and it is directed to the aortic plaque along with the flow of monocytes and prevents the formation of foamy cells and the polarization of macrophages from the inflammatory M1 phenotype to the anti-inflammatory M2 phenotype.
“The loaded drug also targets the upstream inflammatory pathways with anti-inflammatory effects compared to common drugs (like Canakinumab),” Mehrzad Salakjani said, adding that the biocompatible and anti-inflammatory cellular nanospecies can be considered and used as a potential platform for the immunotherapy of chronic inflammatory diseases, specially atherosclerosis in humans.
Arteriosclerosis is a type of vascular disease where the blood vessels carrying oxygen away from the heart (arteries) become damaged from factors such as high cholesterol, high blood pressure, diabetes and certain genetic influences.
4155/v
